Lung Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_23_3548 - Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumors Treated By IMRT Based -Stereotactic Ablative Body Radiation Therapy (SABR)

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumors Treated By IMRT Based -Stereotactic Ablative Body Radiation Therapy (SABR)
A. M. Mihai1, N. Elbeltagi2, P. Thirion2, C. Marshall1, D. Hickey1, A. Bilfalk-Kelly2, J. Westrup1, and J. G. Armstrong1; 1Beacon Hospital, Dublin, Ireland, 2St. Luke's Radiation Oncology Network, Dublin, Ireland

Purpose/Objective(s): To report the late toxicity and long term local control of IMRT- based SABR in patients (pts) with ultra-central lung tumors, treated in a single institution.

Materials/Methods: This is a retrospective review of 50 pts with ultra-central tumors treated by SABR, from May 2008 to April 2016. All pts had minimum 6 months (mts) follow-up (FU) post-SABR. Ultra-central location was defined as tumor abutting or involving trachea, main or lobar bronchi (airways). Respiratory management was used in all pts. Radiation schedule was at physician preference. Treatment was delivered using a medical linear accelerator. Late toxicity (>6months post-SABR) and local control (LC-absence of local progression) were analysed. Descriptive analysis, Kaplan Meier, log-rank test and Cox regression were used to assess the outcomes. Late toxicity was graded according to CTCAE v.4. Data was censored at the last known follow-up or death.

Results: There were 26 males (52%) and 24 females (48%), with a median age of 72.5 years old (34 - 85) and median KPS = 80 (60-100). 33 pts (66%) had inoperable primary NSCLC and 17 (34%) lung metastases. The median gross tumor volume (GTV) and median planning target volume (PTV) were 16.73cc (1.7 -136.85), and 56.4 cc (7.7 – 307) respectively. Most commonly used dose fractionation was 60 Gy/ 8fx in 43 pts (86%) . The median D98%PTV - was 58.94Gy (21.5-62.96), and the median D2% PTV= 64 Gy (43.11 – 79.5). In 10 pts dose painting was used to spare the airways, leading to D98% PTV < 90% in 9 pts and D98% GTV < 90% in 7 pts. One pt. was lost of FU. With a median FU of 25.5mts (7.43-92.68), significant late toxicity (> G3) occurred in 8 pts (16%): G3 cough– 1pt (2%), G3 aspiration- 1pt (2%), G3 fatigue – 1pt (2%), G3 dyspnea – 1pt (2%). G5 hemoptysis was observed in 4pts (8%), after a median of 12.7 mts (11.4- 54.6) from SABR: in 2pts (4 %) was undeniably SABR-induced (pts with complete metabolic response) and in 2 pts (4%) occurred concomitantly with local progression (LP). No correlation between airways DVH parameters and risk of hemoptysis could be identified (p=0.6). At the last known FU, LC was observed in 43pts (86%); most of the LPs (5 of 7) were observed more than 24 months from SABR. None of the dosimetric or clinical parameters were correlated with LC.

Conclusion: In patients with ultra-central lung tumors, SABR achieves high local control, similar to that reported for peripheral tumors. While fatal hemoptysis was observed in 8% of the patients, in 4% of them it was definitely related to SABR only.
Number patients %
Dose fractionation
60Gy/8fx 43 86
48GY/4fx 3 6
50Gy/10fx 3 6
40Gy/5fx 1 2
Respiratory management
Gated 8 16
Free breathing non-gated 28 56
Breath-hold 14 28
Airways DVH parameters
40Gy IDL circumferential 22 42
Dose to 1cc (median±StDev) 51.8Gy±13.9(5.17-64.3)
Dose to 5cc (median±StDev) 45.2Gy±14.5(4.4-63.5)
Table 1: Dose fractionation, respiratory management and airways DVH parameters.Legend: fx-fraction, DVH-dose volume histogram, IDL – isodose line, StDev-standard deviation

Author Disclosure: A.M. Mihai: advisor; Medisprof Cancer Centre. Director of Oncology Research; Beacon Hospital. N. Elbeltagi: None. P. Thirion: Visiting Consultant; Beacon Hospital. National Training coordinator; Faculty of Radiologists, RCSI. C. Marshall: None. D. Hickey: None. A. Bilfalk-Kelly: None. J. Westrup: Independent Contractor; Beacon Hospital. Medical Director; Beacon Hospital. CHair Board; Cancer Trials Ireland. J.G. Armstrong: Visiting Consultant; Beacon Hospital. Medical Director Dept Radiation Oncology; Beacon Hospital.

Send Email for Alina Mihai


Assets

TU_23_3548 - Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumors Treated By IMRT Based -Stereotactic Ablative Body Radiation Therapy (SABR)



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumors Treated By IMRT Based -Stereotactic Ablative Body Radiation Therapy (SABR)